Research and Development Investment: Amphastar Pharmaceuticals, Inc. vs Xencor, Inc.

R&D Investment Trends: Amphastar vs. Xencor

__timestampAmphastar Pharmaceuticals, Inc.Xencor, Inc.
Wednesday, January 1, 20142842700018516000
Thursday, January 1, 20153706500034140000
Friday, January 1, 20164119900051872000
Sunday, January 1, 20174341500071772000
Monday, January 1, 20185756400097501000
Tuesday, January 1, 201968853000118590000
Wednesday, January 1, 202067229000169802000
Friday, January 1, 202160932000192507000
Saturday, January 1, 202274771000199563000
Sunday, January 1, 202373741000253598000
Loading chart...

Unleashing the power of data

A Decade of R&D Investment: Amphastar vs. Xencor

In the competitive landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xencor, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Xencor's R&D expenses surged by over 1,270%, peaking at approximately $254 million in 2023. This aggressive investment reflects Xencor's commitment to pioneering new therapies. In contrast, Amphastar's R&D spending grew by a more modest 160%, reaching around $74 million in the same year. This difference highlights Amphastar's steady, yet cautious approach to innovation. The data underscores a broader trend in the pharmaceutical industry: while some companies opt for rapid expansion in R&D to capture market share, others prefer a more measured pace, balancing innovation with financial prudence. As the industry evolves, these strategies will shape the future of healthcare breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025